5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.69▲ | 2.66▲ | 2.65▲ | 2.22▲ | 1.85▲ |
MA10 | 2.65▲ | 2.62▲ | 2.53▲ | 2.00▲ | 2.00▲ |
MA20 | 2.63▲ | 2.45▲ | 2.26▲ | 1.77▲ | 2.10▲ |
MA50 | 2.52▲ | 2.09▲ | 1.99▲ | 2.00▲ | 2.97▼ |
MA100 | 2.22▲ | 1.93▲ | 1.80▲ | 2.07▲ | 4.03▼ |
MA200 | 2.02▲ | 1.73▲ | 1.76▲ | 2.78▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | 0.009▲ | 0.043▲ | 0.130▲ | 0.050▲ |
RSI | 65.063▲ | 80.596▲ | 83.427▲ | 78.038▲ | 54.671▲ |
STOCH | 95.255▲ | 83.979▲ | 93.487▲ | 87.724▲ | 28.763 |
WILL %R | -1.961▲ | -1.408▲ | -0.690▲ | -0.412▲ | -24.347▲ |
CCI | 100.309▲ | 90.842 | 99.783 | 224.043▲ | 36.769 |
Monday, April 28, 2025 07:08 PM
Short interest in Vigil Neuroscience Inc (NASDAQ:VIGL) decreased during the last reporting period, falling from 423.46K to 422.30K. This put 1.32% of the company's publicly available shares short.
|
Monday, April 21, 2025 05:00 PM
April 02, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
|
Saturday, April 12, 2025 05:31 PM
Update 11.32 AM EST: Adds comments from Mizuho Shares of Vigil Neuroscience (NASDAQ:VIGL) rose ~18% in the premarket on Thursday after the Sanofi (SNY)-backed biotech said that it expects to ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
02/05/25 | 2.46 | 2.715 | 2.46 | 2.71 | 130,294 |
01/05/25 | 2.13 | 2.71 | 2.11 | 2.56 | 497,910 |
30/04/25 | 1.86 | 2.24 | 1.855 | 2.10 | 173,564 |
29/04/25 | 1.84 | 1.94 | 1.84 | 1.92 | 64,325 |
28/04/25 | 1.78 | 1.8696 | 1.77 | 1.82 | 44,001 |
25/04/25 | 1.79 | 1.82 | 1.745 | 1.79 | 60,306 |
24/04/25 | 1.82 | 1.87 | 1.75 | 1.79 | 97,499 |
23/04/25 | 1.81 | 1.86 | 1.77 | 1.81 | 73,799 |
22/04/25 | 1.73 | 1.85 | 1.70 | 1.80 | 129,792 |
21/04/25 | 1.75 | 1.785 | 1.68 | 1.68 | 109,241 |
|
|
||||
|
|
||||
|
|